Histological and immunohistochemical evaluation of basal cell carcinoma following curettage and electrodessication

Filho, Lauro Lourival Lopes; Alchorne, Alice de Oliveira de Avelar; Pereira, Gerson Cotta; Lopes, Lauro Rodolpho Soares; Carvalho, Teresinha Castelo Branco

doi:10.1111/j.1365-4632.2008.03284.x

Cited by 6 publications

(7 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Histologic evidence of persistent BCCs occurred in five of the 20 BCCs. The conclusion from this study was that there is at least a 25% probability of tumor persistence following two cycles of ED&C in these high‐risk tumors 51 …”

Section: Treatment Optionsmentioning

confidence: 81%

See 1 more Smart Citation

Basal cell carcinoma: evidence‐based medicine and review of treatment modalities

Kwasniak

Garcia-Zuazaga

2011

Int J Dermatology

View full text Add to dashboard Cite

show abstract

Section: Treatment Optionsmentioning

confidence: 81%

“…The conclusion from this study was that there is at least a 25% probability of tumor persistence following two cycles of ED&C in these high-risk tumors. 51 Most of the dermatologic surgery community would agree that the NYU data by Silverman et al accurately reflects the true recurrence rates of BCCs treated with ED&C.…”

Section: Standard Surgical Excisionmentioning

confidence: 99%

Basal cell carcinoma: evidence‐based medicine and review of treatment modalities

Kwasniak

Garcia-Zuazaga

2011

Int J Dermatology

View full text Add to dashboard Cite

show abstract

“…51 Tumour clearance of lesions <2 cm in high-risk sites, assessed histologically following excision, ranged between 53% and 75%. 52,53 Advantages of ED&C in treating small lesions are that it is inexpensive, tissue-sparing, and generally well tolerated. Disadvantages include the potential for hypopigmented scars, need for specialized training, and lack of histologic confirmation of clearance.…”

Section: Electrodesiccation and Curettagementioning

confidence: 99%

Non-melanoma Skin Cancer in Canada Chapter 4: Management of Basal Cell Carcinoma

et al. 2015

View full text Add to dashboard Cite

Background: Basal cell carcinoma (BCC) is the most common malignancy. Growth of BCCs leads to local destruction of neighbouring healthy skin and underlying tissue and can result in significant functional and cosmetic morbidity. Objective: To provide guidance to Canadian health care practitioners regarding management of BCCs. Methods: Literature searches and development of graded recommendations were carried out as discussed in the accompanying Introduction. Results: Although BCCs rarely metastasize, they can be aggressive and disfiguring. This chapter describes the natural history and prognosis of BCCs. Risk stratification is based on clinical features, including the site and size of the tumour, its histologic subtype (nodular vs sclerosing), and its history of recurrence. Conclusions: Various options should be considered for BCC treatment, including cryosurgery, curettage, and topical or photodynamic approaches, as well as fixed-margin surgery and Mohs micrographic surgery. Stratification of recurrence risk for individual BCCs determines the most appropriate therapeutic course. RésuméContexte : Le carcinome basocellulaire (CBC) est le cancer le plus répandu. La croissance d'un CBC mène à la destruction locale de la peau saine environnante et des tissus sous-jacents et peut causer une morbidité fonctionnelle et cosmétique importante. Objectif : Fournir des conseils aux professionnels canadiens de la santé au sujet de la gestion des CBC. Méthode : Nous avons procédé à une étude documentaire et à l'élaboration de catégories de recommandations, comme on peut le lire dans l'introduction connexe. Résultats : Le CBC forme rarement des métastases, mais il peut être agressif et défigurant. Ce chapitre décrit l'évolution et le pronostic du CBC. La stratification du risque est fondée sur les caractéristiques cliniques, y compris l'emplacement et la taille de la tumeur, et son sous-type histologique (nodulaire ou sclérosant), et sur les antécédents de récurrence. Conclusion : Diverses options devraient être envisagées dans le traitement du CBC, y compris la cryochirurgie, le curetage et les approches topiques ou photodynamiques, ainsi que la chirurgie à marge déterminée et la chirurgie micrographique de Mohs. La stratification du risque de récurrence de chaque CBC individuel détermine le traitement thérapeutique le plus approprié.

show abstract

“…Filho et al (2008) conducted a study using BerEP4 testing on 20 BCC specimens to ensure the edge of the incision has been free of BCC cells after curettage treatment and two cycles of electrofulguration. The test resulted in 5 BCC specimens (25%) being positive for remaining BCC cells [ 31 ].…”

Section: Berep4 Use After Surgery For Prevention Of Recurrencementioning

confidence: 99%

The Use of BEREP4 Immunohistochemistry Staining for Detection of Basal Cell Carcinoma

Sunjaya

Tan

2017

Journal of Skin Cancer

View full text Add to dashboard Cite

Basal Cell Carcinoma (BCC) is the most common type of malignant cancer found in the world today with a 3–10% increase in incidence each year. The American Cancer Society reported that 8 out of 10 patients with skin cancer are suffering from BCC with over 2 million new cases each year. BCC needs to be detected at the early stages to prevent local destruction causing disabilities to patients and increasing treatment costs. Furthermore, BCC patients who have undergone surgery are still at risk for recurrence, especially when the surgery performed fails to remove all the BCC cells, even when conventional histopathological testing after surgery has reported a surgically free margin. This review aims to evaluate studies on the use of BerEP4 immunohistochemistry staining on pathological sections of various types of BCC as well as its shortfalls. BerEP4 is a monoclonal antibody which detects specific epithelial-glycoprotein-adhesion-molecules (EpCAM) found on BCC cells. Various studies have shown that BerEP4 has a high sensitivity and specificity in detecting only BCC cells. The use of BerEP4 immunohistochemistry testing for the routine examination of cases of BCC is expected to be able to increase and improve early diagnosis as well as prevent recurrence after surgery.

show abstract

Histological and immunohistochemical evaluation of basal cell carcinoma following curettage and electrodessication

Cited by 6 publications

References 13 publications

Basal cell carcinoma: evidence‐based medicine and review of treatment modalities

Basal cell carcinoma: evidence‐based medicine and review of treatment modalities

Non-melanoma Skin Cancer in Canada Chapter 4: Management of Basal Cell Carcinoma

The Use of BEREP4 Immunohistochemistry Staining for Detection of Basal Cell Carcinoma

Contact Info

Product

Resources

About